Management also lowered the midpoint ... The Motley Fool Stock Advisor analyst team just identified what they believe are the ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q3 2024 earnings call. [Operator ...

In addition to top-line figures that missed Wall Street expectations, management ... team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

The reactions to Donald's Trump's victory across the crypto, currency, and stock markets. Super Micro's woes, and the outlook for a company with no auditor, no annual report and, perhaps soon, no ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

In all likelihood, when the management team at Eli Lilly and Company announces financial results for the third quarter of the 2024 fiscal year, that growth will be considered rather significant.

With its 1-star rating, we believe Eli Lilly’s stock is significantly overvalued ... In addition to leading the sector team, she covers biopharma firms in the US and Europe, focusing mostly ...

NEW YORK (AP) — U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies overshadowed a ... Try refreshing your browser, or tap here to see other videos from our team. The ...